Zydus Lifesciences Limited has informed the Exchange about General Updates
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Zydus Therapeutics, a wholly owned subsidiary of Zydus Lifesciences, received US FDA Priority Review for its New Drug Application (NDA) for saroglitazar. The drug is proposed for treating Primary Biliary Cholangitis (PBC) in adults who have inadequate response to ursodeoxycholic acid (UDCA) or as monotherapy for patients unable to tolerate UDCA. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 2026. Priority Review designation typically indicates significant potential clinical benefit and accelerates the review timeline. This marks a key milestone for Zydus in the US market.
Priority Review status is a positive regulatory signal that could lead to FDA approval within the set timeline, potentially opening a significant revenue opportunity for Zydus in the US PBC treatment market.